• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Survival of castration-resistant prostate cancer patients treated with dendritic-tumor cell hybridomas is negatively correlated with changes in peripheral blood CD56 CD16 natural killer cells.

作者信息

Haque Chowdhury Helena, Hawlina Simon, Gabrijel Mateja, Trkov Bobnar Saša, Kreft Marko, Lenart Gordan, Cukjati Marko, Kopitar Andreja Nataša, Kejžar Nataša, Ihan Alojz, Ležaič Luka, Grmek Marko, Kmetec Andrej, Jeras Matjaž, Zorec Robert

机构信息

Laboratory of Cell Engineering, Celica Biomedical, Ljubljana, Slovenia.

Laboratory of Neuroendocrinology - Molecular Cell Physiology, Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

出版信息

Clin Transl Med. 2021 Aug;11(8):e505. doi: 10.1002/ctm2.505.

DOI:10.1002/ctm2.505
PMID:34459140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8387785/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/839e/8387785/0069cec36064/CTM2-11-e505-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/839e/8387785/e326ba3e79f7/CTM2-11-e505-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/839e/8387785/c7c04c75359f/CTM2-11-e505-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/839e/8387785/0069cec36064/CTM2-11-e505-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/839e/8387785/e326ba3e79f7/CTM2-11-e505-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/839e/8387785/c7c04c75359f/CTM2-11-e505-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/839e/8387785/0069cec36064/CTM2-11-e505-g001.jpg

相似文献

1
Survival of castration-resistant prostate cancer patients treated with dendritic-tumor cell hybridomas is negatively correlated with changes in peripheral blood CD56 CD16 natural killer cells.接受树突状肿瘤细胞杂交瘤治疗的去势抵抗性前列腺癌患者的生存率与外周血CD56 CD16自然杀伤细胞的变化呈负相关。
Clin Transl Med. 2021 Aug;11(8):e505. doi: 10.1002/ctm2.505.
2
Circulating CD16+CD56+ nature killer cells indicate the prognosis of colorectal cancer after initial chemotherapy.循环 CD16+CD56+自然杀伤细胞预示初始化疗后结直肠癌的预后。
Med Oncol. 2019 Sep 6;36(10):84. doi: 10.1007/s12032-019-1307-8.
3
Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56CD16NKp80 and Express KIR2DL2/DL3 and KIR3DL1.由人诱导多能干细胞生成的自然杀伤细胞成熟为 CD56CD16NKp80，并表达 KIR2DL2/DL3 和 KIR3DL1。
Front Immunol. 2021 May 4;12:640672. doi: 10.3389/fimmu.2021.640672. eCollection 2021.
4
Natural Killer and Natural Killer T Cells in Juvenile Systemic Lupus Erythematosus: Relation to Disease Activity and Progression.自然杀伤细胞和自然杀伤 T 细胞在幼年系统性红斑狼疮中的作用：与疾病活动和进展的关系。
Arch Immunol Ther Exp (Warsz). 2019 Jun;67(3):161-169. doi: 10.1007/s00005-019-00537-6. Epub 2019 Apr 4.
5
CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer.CD3(-)CD16(-)CD56(bright) 免疫调节性自然杀伤细胞在甲状腺乳头状癌患者肿瘤微环境中增加，并与晚期呈负相关。
Thyroid. 2013 Dec;23(12):1561-8. doi: 10.1089/thy.2012.0560. Epub 2013 Nov 6.
6
Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.脂肪细胞通过改变肿瘤细胞中PD-L1/NKG2D配体水平，影响去势抵抗性前列腺癌细胞对NK细胞细胞毒性作用产生抗性。
Prostate. 2018 Apr;78(5):353-364. doi: 10.1002/pros.23479. Epub 2018 Jan 12.
7
Early Cytomegalovirus Reactivation and Expansion of CD56CD16DNAM1 Natural Killer Cells Are Associated with Antileukemia Effect after Haploidentical Stem Cell Transplantation in Acute Leukemia.早期巨细胞病毒再激活和 CD56CD16DNAM1 自然杀伤细胞的扩增与急性白血病患者接受单倍体造血干细胞移植后的抗白血病效应有关。
Biol Blood Marrow Transplant. 2019 Oct;25(10):2070-2078. doi: 10.1016/j.bbmt.2019.06.008. Epub 2019 Jun 15.
8
CD56CD16 natural killer cells are shifted toward an IFN-γ-promoting phenotype with reduced regulatory capacity in osteoarthritis.在骨关节炎中，CD56CD16 自然杀伤细胞向 IFN-γ 促进表型转变，其调节能力降低。
Hum Immunol. 2019 Oct;80(10):871-877. doi: 10.1016/j.humimm.2019.07.283. Epub 2019 Jul 18.
9
CD56 CD16 Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α.CD56 CD16 自然杀伤细胞表型分析在接受癌症疫苗和干扰素-α治疗的黑色素瘤患者中的应用。
Front Immunol. 2019 Jan 29;10:14. doi: 10.3389/fimmu.2019.00014. eCollection 2019.
10
Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.结直肠癌患者循环 T、NK 和 NKT 细胞亚群的特征：外周血免疫细胞谱。
Cancer Immunol Immunother. 2019 Jun;68(6):1011-1024. doi: 10.1007/s00262-019-02343-7. Epub 2019 May 3.

引用本文的文献

1
Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives.前列腺癌的免疫检查点抑制剂疗法：现状与未来展望
Biomolecules. 2025 May 22;15(6):751. doi: 10.3390/biom15060751.
2
The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise.新兴免疫疗法在前列腺癌治疗中的应用：进展、困境与前景。
Front Immunol. 2025 Mar 12;16:1544882. doi: 10.3389/fimmu.2025.1544882. eCollection 2025.
3
Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide.

本文引用的文献

1
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.血源树突状细胞疫苗接种可诱导免疫应答，与未经化疗的去势抵抗性前列腺癌患者的临床结局相关。
J Immunother Cancer. 2019 Nov 14;7(1):302. doi: 10.1186/s40425-019-0787-6.
2
Circulating CD56 NK cells inversely correlate with survival of melanoma patients.循环 CD56 NK 细胞与黑色素瘤患者的生存呈负相关。
Sci Rep. 2019 Mar 14;9(1):4487. doi: 10.1038/s41598-019-40933-8.
3
Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.
转移性去势抵抗性前列腺癌患者接受恩扎卢胺治疗后的自然杀伤细胞活性。
Sci Rep. 2023 Oct 10;13(1):17144. doi: 10.1038/s41598-023-43937-7.
4
Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer.基于个性化树突状细胞的免疫杂交瘤疫苗治疗前列腺癌的潜力。
Life (Basel). 2023 Jul 1;13(7):1498. doi: 10.3390/life13071498.
5
Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils the Characteristics of the Immune Microenvironment and Prognosis Signature in Prostate Cancer.批量RNA测序和单细胞RNA测序的综合分析揭示了前列腺癌免疫微环境的特征和预后特征。
J Oncol. 2022 Jul 19;2022:6768139. doi: 10.1155/2022/6768139. eCollection 2022.
6
Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number.基于树突状细胞的疫苗可延长患者的生存时间和下一次治疗的时间，与疫苗细胞数量无关。
Biol Direct. 2022 Feb 23;17(1):5. doi: 10.1186/s13062-022-00318-w.
基于树突状细胞-肿瘤融合细胞的癌症疫苗
Int J Mol Sci. 2016 May 26;17(6):828. doi: 10.3390/ijms17060828.
4
Human CD56bright NK Cells: An Update.人类CD56bright自然杀伤细胞：最新进展
J Immunol. 2016 Apr 1;196(7):2923-31. doi: 10.4049/jimmunol.1502570.
5
Advances in the understanding of cancer immunotherapy.癌症免疫疗法认识上的进展。
BJU Int. 2015 Sep;116(3):321-9. doi: 10.1111/bju.12692. Epub 2015 May 18.
6
Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets.乳腺癌患者外周血 NK 细胞为肿瘤诱导的复合亚群。
J Immunol. 2013 Mar 1;190(5):2424-36. doi: 10.4049/jimmunol.1200140. Epub 2013 Jan 28.
7
Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma.转移性黑色素瘤患者外周血中CD16阴性自然杀伤细胞的扩增。
Clin Dev Immunol. 2011;2011:316314. doi: 10.1155/2011/316314. Epub 2011 Feb 23.
8
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
9
Monitoring lysosomal fusion in electrofused hybridoma cells.监测电融合杂交瘤细胞中的溶酶体融合。
Biochim Biophys Acta. 2008 Feb;1778(2):483-90. doi: 10.1016/j.bbamem.2007.10.013. Epub 2007 Oct 23.
10
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.基于树突状细胞的激素难治性前列腺癌多表位免疫疗法
Cancer Immunol Immunother. 2006 Dec;55(12):1524-33. doi: 10.1007/s00262-006-0157-3. Epub 2006 Apr 13.